__NUXT_JSONP__("/drugs/Trametinib_Dimethyl_Sulfoxide", (function(a,b,c,d,e){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[{brand:c,indication:"1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKINIST ® is indicated, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1)] . 1.2 Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection [see Dosage and Administration (2.1)]. 1.3 BRAF V600E Mutation-Positive Metastatic NSCLC MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration (2.1)] . 1.4 BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options [see Dosage and Administration (2.1)] .",manufacturer:"Novartis Pharmaceuticals Corporation",splSetId:"0002ad27-779d-42ab-83b5-bc65453412a1"}],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK\u002FERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine\u002Fthreonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS\u002FRAF\u002FMEK\u002FERK signaling pathway that regulates cell growth.",fdaUniiCode:"BSB9VJ5TUT",identifier:"C152711",preferredName:d,semanticType:"Organic Chemical",subclassOf:["C129825","C69145"],synonyms:[c,"TRAMETINIB DIMETHYL SULFOXIDE",d]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTrametinib_Dimethyl_Sulfoxide",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("","Trametinib_Dimethyl_Sulfoxide","Mekinist","Trametinib Dimethyl Sulfoxide","2021-10-30T13:33:55.803Z")));